The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious form of fatty liver disease. The approval makes Wegovy the only GLP-1 therapy ...

The FDA issued a complete response letter to PTC Therapeutics for vatiquinone, citing insufficient evidence of efficacy, preventing approval as the first pediatric therapy for Friedreich’s ataxia (FA) ...